GBM AGILE: Global Adaptive Trial Master Protocol: an International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

开始日期2019-07-30

申办/合作机构

朴莱雷斯集团

[+5]

NCT03364400 / Active, not recruiting临床1期

A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

开始日期2017-11-28

申办/合作机构

Vigeo Therapeutics, Inc.

100 项与 VT-1021 相关的临床结果

登录后查看更多信息

100 项与 VT-1021 相关的转化医学

登录后查看更多信息

100 项与 VT-1021 相关的专利（医药）

登录后查看更多信息

项与 VT-1021 相关的文献（医药）

Communications Medicine

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Article

作者: Mahoney, James ; Vincent, Melanie Y ; Zota, Victor ; Juric, Dejan ; Watnick, Jing ; Chen, Jian Jenny ; Patel, Manish R ; Cieslewicz, Michael ; Bullock, Andrea ; Watnick, Randolph S ; Mahalingam, Devalingam ; Shepard, Dale ; Battiste, James ; Liu, Joyce ; Wen, Patrick Y ; Li, Wendy ; Wang, Suming ; Pant, Shubham ; Peereboom, David ; Fyfe, Susanne ; Selfridge, Jennifer Eva

AbstractBackgroundPreclinical studies have demonstrated that VT1021, a first-in-class therapeutic agent, inhibits tumor growth via stimulation of thrombospondin-1 (TSP-1) and reprograms the tumor microenvironment. We recently reported data from the dose escalation part of a phase I study of VT1021 in solid tumors. Here, we report findings from the dose expansion phase of the same study.MethodsWe analyzed the safety and tolerability, clinical response, and biomarker profile of VT1021 in the expansion portion of the phase I study (NCT03364400). Safety/tolerability is determined by adverse events related to the treatment. Clinical response is determined by RECIST v1.1 and iRECIST. Biomarkers are measured by multiplexed ion beam imaging and enzyme-linked immunoassay (ELISA).ResultsFirst, we report the safety and tolerability data as the primary outcome of this study. Adverse events (AE) suspected to be related to the study treatment (RTEAEs) are mostly grade 1–2. There are no grade 4 or 5 adverse events. VT1021 is safe and well tolerated in patients with solid tumors in this study. We report clinical responses as a secondary efficacy outcome. VT1021 demonstrates promising single-agent clinical activity in recurrent GBM (rGBM) in this study. Among 22 patients with rGBM, the overall disease control rate (DCR) is 45% (95% confidence interval, 0.24-0.67). Finally, we report the exploratory outcomes of this study. We show the clinical confirmation of TSP-1 induction and TME remodeling by VT1021. Our biomarker analysis identifies several plasmatic cytokines as potential biomarkers for future clinical studies.ConclusionsVT1021 is safe and well-tolerated in patients with solid tumors in a phase I expansion study. VT1021 has advanced to a phase II/III clinical study in glioblastoma (NCT03970447).

Communications Medicine

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Article

作者: Watnick, Jing ; Mahalingam, Devalingam ; Chao, Judy ; Vincent, Melanie Y ; Mahoney, James ; Chen, Jian Jenny ; Bullock, Andrea ; Wang, Suming ; Harb, Wael ; Pestana, Harold ; Patnaik, Amita ; Watnick, Randolph S ; Cieslewicz, Michael

AbstractBackgroundVT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding to CD36 and CD47 to induce tumor and endothelial cell apoptosis as well as immune modulation in the TME.MethodsStudy VT1021-01 (ClinicalTrials.gov ID NCT03364400) used a modified 3 + 3 design. The primary objective was to determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Safety, tolerability, and pharmacokinetics (PK) were assessed. Patients were dosed twice weekly intravenously in 9 cohorts (0.5–15.6 mg/kg). Safety was evaluated using CTCAE version 5.0 and the anti-tumor activity was evaluated by RECIST version 1.1.ResultsThe RP2D of VT1021 is established at 11.8 mg/kg. VT1021 is well tolerated with no dose-limiting toxicities reported (0/38). The most frequent drug-related adverse events are fatigue (15.8%), nausea (10.5%), and infusion-related reactions (10.5%). Exposure increases proportionally from 0.5 to 8.8 mg/kg. The disease control rate (DCR) is 42.9% with 12 of 28 patients deriving clinical benefit including a partial response (PR) in one thymoma patient (504 days).ConclusionsVT1021 is safe and well-tolerated across all doses tested. RP2D has been selected for future clinical studies. PR and SD with tumor shrinkage are observed in multiple patients underscoring the single-agent potential of VT1021. Expansion studies in GBM, pancreatic cancer and other solid tumors at the RP2D have been completed and results will be communicated in a separate report.

Cells

The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target

Review

作者: Zuppe, Hannah T. ; Kurokawa, Manabu ; Feng, William W.

Cluster of differentiation 36 (CD36) is a cell surface scavenger receptor that plays critical roles in many different types of cancer, notably breast, brain, and ovarian cancers. While it is arguably most well-known for its fatty acid uptake functions, it is also involved in regulating cellular adhesion, immune response, and apoptosis depending on the cellular and environmental contexts. Here, we discuss the multifaceted role of CD36 in cancer biology, such as its role in mediating metastasis, drug resistance, and immune evasion to showcase its potential as a therapeutic target. We will also review existing approaches to targeting CD36 in pre-clinical studies, as well as discuss the only CD36-targeting drug to advance to late-stage clinical trials, VT1021. Given the roles of CD36 in the etiology of metabolic disorders, such as atherosclerosis, diabetes, and non-alcoholic fatty liver disease, the clinical implications of CD36-targeted therapy are wide-reaching, even beyond cancer.

项与 VT-1021 相关的新闻（医药）

2023-07-13

·BioSpace

Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient

CAMBRIDGE, Mass., July 13, 2023 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, is pleased to announce that a complete response patient (CR) in Glioblastoma (GBM) cohort from first in human study VT1021-01 (NCT03364400) has now completed 3 full years of dosing with VT1021. When joining the study in July of 2020 the patient had a recurrent case of GBM. After multiple cycles of dosing with VT1021, the tumor was no longer detectable. Now, after 3 years of dosing the tumor continues to be undetectable on regular MRI scans. "The Vigeo Team continues to be encouraged at how well this patient has responded to VT1021 therapy" said Jing Watnick, COO of Vigeo Therapeutics, "Vigeo is currently testing the potential of VT1021 therapy in both newly diagnosed and recurrent GBM patients as part of an ongoing phase II/III clinical study (NCT03970447)." VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME). Tsp-1 blocks the CD47 immune checkpoint and engages CD36 to induce tumor cell apoptosis, inhibit angiogenesis, activate cytotoxic T cells (CTL), and reprogram macrophages from the M2 to M1 phenotype. Vigeo recently reported the outcome of a GBM cohort of recurrent subjects treated with VT1021 as a single agent in which a group of 22 evaluable subjects with rGBM, 3 had a complete response (CR), 1 had a partial response (PR), and 6 had stable disease (SD) with an average study duration of over 120 days. Historically, rGBM patients have a response rate of less than 5% and a median progression free survival of 48 days. About VT1021 Vigeo's lead asset, VT1021, is a first-in-class dual-modulating compound that blocks the CD47 immune checkpoint and activates CD36, which induces apoptosis in tumors and endothelial cells, and increases the M1:M2 macrophage ratio. VT1021 achieves these biological effects via stimulation of thrombospondin-1 (Tsp-1). The goal of these dual-modulating effects is conversion of immuno-suppressive, or "cold," tumors that that are associated with poor response to immuno-oncology agents, to immuno-stimulated, or "hot," tumors that are more susceptible to attack from the body's immune system. Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors. About Vigeo Therapeutics Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug development pipeline being led by VT1021, its dual-modulating compound that blocks the CD47 immune checkpoint and reprograms CD36 mediated activities. VT1021 has been investigated as a single agent in a Phase I/II clinical trial in patients with glioblastoma, pancreatic cancer and other solid tumors, and is currently undertaking late-stage clinical studies. For more information visit vigeotx.com

免疫疗法临床研究临床结果

2023-06-11

·药明康德

实现90%靶病灶控制的快速生产非病毒CAR-T疗法、明星PROTAC疗法结果亮眼… | 一周盘点

▎药明康德内容团队编辑本期看点1. 强生（Johnson & Johnson）旗下的杨森（Janssen）公司公布用于治疗复发或难治性多发性骨髓瘤的双特异性抗体talquetamab积极长期随访数据，与Darzalex Faspro联用，总缓解率（ORR）超过70%，12个月时的总生存率超过90%。2. 通过气溶胶形式给药的基因疗法4D-710具有治疗囊性纤维化的潜力，在超过90%的肺气道细胞中观察到了靶标蛋白广泛且一致的表达。3. 用于治疗晚期转移性去势抵抗性前列腺癌（mCRPC）的PROTAC蛋白降解剂ARV-766早期临床结果亮眼。4. Allogene Therapeutics公司公布CAR-T细胞疗法ALLO-501A的早期临床新数据，2名复发性/难治性大B细胞淋巴瘤患者已维持完全缓解（CR）超过30个月。5. 耐化疗的转基因自体γδT细胞疗法INB-200用于治疗新诊断的多形性胶质母细胞瘤，在早期研究中使100%患者的中位无进展生存期（PFS）超过了历史上此类患者的中位PFS。6. 能够在非病毒基因递送后实现隔天回输的UltraCAR-T细胞疗法PRGN-3005公布积极早期数据，在中位治疗线数≥8线晚期铂类耐药卵巢癌患者中，90%的单个靶病灶稳定或达到了部分缓解（PR）。药明康德内容团队整理Talquetamab：公布1/2期临床试验的长期随访数据杨森公司公布了其双特异性抗体talquetamab用于治疗复发或难治性多发性骨髓瘤的关键临床试验的积极长期随访数据。Talquetamab是一款在研、皮下注射、潜在“first-in-class”的双特异性抗体，同时靶向GPRC5D与CD3分子。其中GPRC5D是表达在多发性骨髓瘤细胞上的靶标，其表达不会随着时间而减少，而CD3则是T细胞受体，与活化T细胞有关。2022年12月，杨森公司向美国FDA递交了talquetamab的生物制品许可申请（BLA）。此次公布的数据显示，talquetamab单药或与Darzalex Faspro联用，在多发性骨髓瘤患者中均展现出良好的安全性和有效性。在talquetamab单药研究中，两种剂量的ORR相似。中位随访时间为12.7个月时，0.8 mg/kg每两周一次（Q2W）剂量组的ORR为71.7%，60.7%的患者达到了非常好的部分缓解（VGPR），CR率为9%，12个月时的总生存率为77.4%，无进展生存率为54.4%。中位随访时间为18.8个月时，0.4 mg/kg每周一次（QW）剂量组的ORR为74.1%，59.4%的患者达到了VGPR或更好，CR率为9.8%，12个月时的总生存率为76.4%，无进展生存率为34.9%。在talquetamab联用Darzalex Faspro的研究中，中位随访时间为15个月时，0.8 mg/kg Q2W剂量组的ORR为84%，74%的患者达到了VGPR或更好，CR率为16%，12个月时的总生存率为91.5%，无进展生存率为67.4%。中位随访时间为16.8个月时，0.4 mg/kg QW剂量组的ORR为71.4%，57.1%的患者达到了VGPR或更好，CR率为14.3%，12个月时的总生存率为92.3%，无进展生存率为77.4%。此外，talquetamab的安全性在临床上是可控的，在长期随访中没有观察到新的安全信号。4D-710：公布1/2期临床试验的新数据4D Molecular Therapeutics公司公布了其基因疗法4D-710治疗肺囊性纤维化的1/2期临床试验的新数据。4D-710是一种由治疗性载体A101和优化的CFTR∆R转基因组成的候选疗法。A101载体能够通过气溶胶形式把疗法递送至整个肺部，在气道细胞中实现高效的基因转导和基因表达，且对人类预先存在的抗体具有抵抗力。此次公布的数据显示，3名不符合或不耐受现有CFTR调节剂的肺囊性纤维化患者的生活质量都有显著的改善，肺功能稳定或得到了改善。支气管镜样本结果显示，CFTR蛋白在92-99%的肺气道细胞中被广泛且一致地表达，其水平明显高于用于对照的正常肺组织样本。ARV-766：公布1/2期临床试验的中期数据Arvinas公司公布了其在研PROTAC蛋白降解剂ARV-766用于治疗晚期mCRPC的1/2期临床试验的积极结果。ARV-766旨在降解雄激素受体（AR）的所有临床相关耐药驱动点突变，包括L702H——一种与阿比特龙和其他AR通路新型激素药物（NHA）耐药相关的突变。此次公布的数据显示，ARV-766耐受性良好，并且在接受过多线治疗、NHA治疗后、所有患者群体中显示出潜在疗效，42%的AR配体结合域（LBD）突变患者实现了前列腺特异性抗原（PSA）减少≥50%（PSA50），在AR L702H突变患者中，60%（3/5）达到了PSA50，在同时发生T878/H875/L702突变的患者中，所有3名患者均达到了PSA50。在4名可评估的AR LBD突变患者中，1名达到确认的PR，1名达到未确认的PR。ALLO-501A：公布1期临床试验的新数据Allogene Therapeutics公司公布了其在研“现货型”CAR-T疗法ALLO-501A的1期临床试验的新数据。ALL-501A是一种经基因工程改造、靶向CD19的AlloCAR-T产品。ALLO-501A通过TALEN基因编辑技术破坏TRAC与CD52基因，以减少移植物抗宿主疾病（GvHD）产生的风险。此外，经由基因工程改造的ALL-501A也让病患得以使用ALLO-647进行辅助治疗。ALLO-647是一种抗CD52的单克隆抗体，可以协助病患进行选择性与暂时性的宿主淋巴细胞清除，以在病患体内建立一个更有利于ALL-501A细胞生长的免疫环境。此前，美国FDA授予ALL-501A再生医学先进疗法认定（RMAT），用于治疗复发性/难治性大B细胞淋巴瘤。截至2023年4月20日，使用单剂量ALL-501A联用FCA90淋巴细胞去除方案（氟达拉滨/环磷酰胺/90 mg ALLO-647）的复发性/难治性大B细胞淋巴瘤患者的ORR为67%（8/12），CR率为58%（7/12），6个月时的CR率为42%，2名患者已保持CR超过30个月，1名患者已保持CR超过24个月。安全性方面，未观察到剂量限制毒性（DLT），免疫效应细胞相关神经毒性综合征（ICANS）或移植物抗宿主病。INB-200：公布1期临床试验数据IN8bio公司公布其耐化疗的转基因自体γδT细胞疗法INB-200用于治疗新诊断的多形性胶质母细胞瘤的积极早期数据。INB-200是一种强大的协同治疗方法，能在患者接受化疗时持续存在，并保持其识别、参与和杀死癌细胞的自然能力。此次公布的结果显示，100%（8/8）接受INB-200治疗的患者已超过历史上此类患者的中位PFS，2名接受3剂INB-200的患者已分别保持23.5个月和19.4个月的疾病无进展。此外，INB-200继续表现出可控的安全性，重复给药没有导致毒性特征的变化。PRGN-3005：公布1b期临床试验数据Precigen公司公布了其在研UltraCAR-T细胞疗法PRGN-3005在晚期铂类耐药卵巢癌患者中的安全性和有效性结果。PRGN-3005是利用Precigen的变革性UltraCAR-T治疗平台所开发，一种使用非病毒基因递送系统制造的自体CAR-T细胞疗法，该系统共表达嵌合抗原受体、膜结合白细胞介素-15（mbIL15）和终止开关，使PRGN-3005具有更好的精度和控制。此外，UltraCAR-T平台无需离体扩增缩短了制造时间，使PRGN-3005能够在非病毒基因递送后实现隔天回输。此次公布的结果显示，在中位治疗线数≥8线的晚期（III/IV）复发性铂耐药卵巢癌、输卵管癌和原发性腹膜癌患者中，接受静脉输注PRGN-3005前进行清淋治疗（lymphodepletion）的策略显示出积极的疗效信号，67%（6/9）患者的肿瘤负荷降低，第35天时，89%（8/9）的患者的CA125有降低，90%的单个靶病灶稳定或达到了PR。此外，PRGN-3005耐受性良好，治疗相关不良事件发生率低，无剂量限制性毒性，无神经毒性，细胞因子释放综合征不超过2级。SNK01：公布1/2a期临床试验数据NKGen Biotech公司公布了其自体自然杀伤细胞（NK）细胞疗法SNK4联用化疗治疗非小细胞肺癌（NSCLC）的积极数据。该试验中的患者在接受过酪氨酸激酶抑制剂后进展，均为肺腺癌患者。该研究中，ORR为25%（3/12），疾病控制率（DCR）为100%，其中35%为PR，75%为疾病稳定（SD），中位PFS为143天。DF1001：公布1期临床试验数据Dragonfly Therapeutics公司公布了其潜在“first-in-class”的三特异性NK细胞接合疗法（TriNKET）DF1001用于治疗晚期实体肿瘤的积极早期数据。DF1001靶向HER2，可驱动实体瘤中的先天性和适应性免疫系统的激活。此次公布的结果显示，DF1001已在先前接受过多线（最多达16线）治疗的转移性乳腺癌（MBC），结直肠癌（CRC），NSCLC和胃食管癌患者中表现出抗肿瘤活性。在平均接受过6线治疗的MBC患者（其中大多数为HER2低表达）中，25%达到了临床缓解。AFM24：公布1/2期临床试验的新数据Affimed公司公布了其先天细胞接合剂（innate cell engager，ICE）疗法AFM24用于治疗NSCLC的早期临床结果。该疗法靶向EGFR和CD16A。此次公布的研究结果显示，15名先前接受过多线治疗的患者中有2名达到了PR，5名达到了SD，ORR为13%，DCR为47%。所有SD患者至少维持了3.5个月无进展，其中1名SD患者持续稳定超过了8个月。此外，AFM24单药治疗继续显示出良好的安全性。BNT316/ONC-392：公布1/2期临床试验数据BioNTech公司和OncoC4公司公布了其联合开发的下一代抗CTLA-4单克隆抗体候选药物BNT316/ONC-392的积极早期临床数据。BNT316/ONC-392旨作为一系列实体瘤的单一或联合疗法，目前正处于临床开发的后期阶段。此次公布的数据显示，在27名转移性PD-（L）1耐药的NSCLC患者中，可评估患者的ORR为29.6%，DCR为70.4%，包括1名CR、7名PR和11名SD的患者。该候选疗法具有良好的耐受性，安全性可控。在10名患者（30%）中观察到3-4级的免疫相关不良事件（irAE），这被认为低于类似药物的报告。VT1021：公布1/2期临床试验的新数据Vigeo Therapeutics公司公布了其衍生自PSAP的小分子肽药物VT1021在复发性胶质母细胞瘤患者中的单药活性。VT1021通过与髓源性抑制细胞（MDSC）结合，诱导肿瘤微环境中血栓形成素-1（Tsp-1）的表达。Tsp-1能够阻断CD47免疫检查点并参与CD36诱导肿瘤细胞凋亡，抑制血管生成，激活细胞毒性T细胞（CTL），并把诱导肿瘤生长的M2巨噬细胞重编程为抑制肿瘤生长的M1巨噬细胞。此次公布的结果显示，在22名可评估的患者中，3名达到CR，1名达到PR，6名达到SD，平均研究持续时间超过120天。1名受试者持续接受VT1021治疗，已参与研究近3年，目前没有剩余的可测量病变。从历史上看，这类患者的缓解率低于5%，中位无进展生存期为48天。ATRC-101：公布1b期临床试验数据Atreca公司公布了其靶向肿瘤特异性核糖核蛋白复合物（RNP）的单克隆抗体ATRC-101作为单一疗法，或联用帕博利珠单抗治疗晚期实体瘤患者的1b期临床试验的数据。结果显示，ATRC-101在多种肿瘤类型中观察到临床活性。在高靶点表达的患者中，DCR为59%（10/17)，53%的患者达到SD，6%的患者达到PR。此外，研究人员在这类患者中观察到了更长的PFS。ATRC-101继续保持良好耐受性。IO-202：公布1期临床试验数据Immune-Onc Therapeutics公司公布了其在研抗LILRB4抗体IO-202的早期临床试验数据。该公司此前的研究显示，LILRB4在急性髓系白血病（AML）的免疫抑制和肿瘤浸润中发挥了作用，LILRB4可抑制抗原呈递细胞激活，导致免疫耐受。针对实体瘤的临床前数据表明，IO-202在体外研究中能够增强树突状细胞功能并激活T细胞，且能在体内研究模型中抑制肿瘤生长。在此次针对复发或难治性急性髓系白血病（AML）和慢性髓系单核细胞白血病（CMML）患者的1期试验中，IO-202的耐受性良好，在单药治疗和联合治疗中均表现出令人鼓舞的临床反应。在单药治疗队列中，1名CMML患者表现出超过一年的临床益处，1名AML患者达到了PR。在联合治疗队列中，1名LILRB4表达高的AML患者达到了CR，并持续缓解超过10个月。此外，5名CMML患者中有3名获得了临床益处，包括最佳骨髓缓解（Optimal Marrow Response）。BI-1910：IND申请获得FDA许可BI-1910是BioInvent International公司开发的靶向抗肿瘤坏死因子受体2（TNFR2）的单克隆抗体，IND申请已获得FDA的批准。该候选疗法单药和与帕博利珠单抗联用的1/2a期临床试验将在美国和欧洲展开，首先在肝细胞癌（HCC）和非小细胞肺癌患者中进行探索性的队列研究。PIPE-791：IND申请获得FDA许可PIPE-791是Pipeline Therapeutics公司开发的一种有效的、选择性的、脑渗透性小分子LPA1受体拮抗剂，主要适应症为多发性硬化（MS）。PIPE-791已在体外和体内模型中显示出活性，并在支持IND申请的临床前研究中耐受性良好。该公司有望在2023年下半年开始招募健康受试者。IFx-Hu2.0：公布1b期临床试验数据Morphogenesis公司公布了其新型个体化癌症疫苗IFx-Hu2.0在对免疫检查点抑制剂（ICI）表现出原发耐药的晚期Merkel细胞癌、皮肤鳞状细胞癌患者中的早期临床结果。结果显示，ICI原发耐药的患者在接受IFx-Hu2.0后，有71%（5/7）在再次接受ICI治疗后产生了客观且持久的抗肿瘤反应，并且该候选疗法的安全性良好。ELI-002：公布1期临床试验的中期数据Elicio Therapeutics公司公布了其在研治疗性癌症免疫疗法ELI-002治疗具高复发风险胰腺癌和结直肠癌患者的积极临床试验数据，这些患者携带KRAS G12D和G12R突变。ELI-002由AMP修饰的KRAS突变体（mKRAS）肽段，和一种AMP修饰的免疫刺激寡核苷酸佐剂ELI-004组成，经皮下给药靶向淋巴结。它能产生RAS特异性杀伤性T细胞，以攻击术后残留肿瘤细胞，有望延长癌症患者缓解并可预防未来复发。此疫苗可覆盖99%携带KRAS基因突变的肿瘤。此次公布的数据显示，77%患者的肿瘤生物标志物减少，32%患者的生物标志物实现了完全清除，ELI-002在87%患者中诱发了强有力的mKRAS特异性T细胞反应。安全性方面，ELI-002显示出良好的耐受性，没有剂量限制性毒性或细胞因子释放综合征。大家都在看▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息参考资料（可上下滑动查看）[1] BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO. Retrieved June 5, 2023, from https://www.globenewswire.com/news-release/2023/06/02/2681039/0/en/BioNTech-and-OncoC4-Present-Positive-Phase-1-2-Data-for-Antibody-Candidate-BNT316-ONC-392-in-Hard-to-Treat-NSCLC-at-ASCO.html[2] Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors. Retrieved June 5, 2023, from https://investors.senseibio.com/news-releases/news-release-details/sensei-biotherapeutics-announces-first-patient-dosed-phase-12-0[3] Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment. Retrieved June 5, 2023, from https://bluejaytx.com/bluejay-therapeutics-advances-in-hepatitis-b-and-d-trials-successfully-completes-bjt-778-phase-1a-study-and-begins-phase-1b-trial-enrollment/[4] OnQuality Announces FDA Clearance of IND Application for OQL051, for the Prophylaxis of Chemotherapy-Induced Diarrhea. Retrieved June 5, 2023, from https://www.prnewswire.com/news-releases/onquality-announces-fda-clearance-of-ind-application-for-oql051-for-the-prophylaxis-of-chemotherapy-induced-diarrhea-301844368.html[5] Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate. Retrieved June 5, 2023, from https://www.globenewswire.com/news-release/2023/06/06/2683139/0/en/Emergex-Announces-Positive-Phase-I-Trial-Data-for-DengueTcP-Its-Novel-T-Cell-Priming-Immune-Set-Point-Candidate.html[6] ZielBio to Present Interim Findings from its Phase 1/2, First-in-Human Trial of ZB131 at 2023 ASCO Annual Meeting. Retrieved June 5, 2023, from https://www.prnewswire.com/news-releases/zielbio-to-present-interim-findings-from-its-phase-12-first-in-human-trial-of-zb131-at-2023-asco-annual-meeting-301840821.html[7] Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting:Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes. Retrieved June 5, 2023, from https://panbela.com/wp-content/uploads/2023/05/PBLA-PR-IDS-POSTER-PRES-01JUN2023.pdf[8] Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Retrieved June 5, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2682035/0/en/Treos-Bio-Announces-Presentation-of-Final-Results-from-Phase-1b-Study-of-PolyPEPI1018-Immunotherapy-for-Late-Stage-Metastatic-Colorectal-Cancer-at-2023-American-Society-of-Clinical.html[9] Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting. Retrieved June 5, 2023, from https://www.businesswire.com/news/home/20230605005033/en[10] Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting. Retrieved June 5, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2681880/0/en/Portage-Biotech-Reports-Updated-Interim-Data-for-Lead-iNKT-Engager-PORT-2-in-a-Phase-1-2-Trial-for-the-Treatment-of-Advanced-Melanoma-and-Metastatic-Non-Small-Cell-Lung-Cancer-at-t.html[11] NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting. Retrieved June 5, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2681928/0/en/NexImmune-Presents-Initial-Positive-Data-from-the-NEXI-001-Phase-1-Trial-for-Relapsed-Refractory-Post-Allo-HSCT-AML-at-the-American-Society-of-Clinical-Oncology-2023-Annual-Meeting.html[12] Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791. Retrieved June 8, 2023, from https://www.businesswire.com/news/home/20230608005323/en[13] Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations. Retrieved June 8, 2023, from https://www.globenewswire.com/news-release/2023/06/08/2684609/0/en/Arvinas-Announces-Interim-Data-from-the-ARV-766-Phase-1-2-Dose-Escalation-and-Expansion-Trial-Showing-Promising-Signals-of-Efficacy-in-Late-line-mCRPC-Including-in-Patients-with-AR.html[14] Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023. Retrieved June 8, 2023, from https://www.businesswire.com/news/home/20230607005899/en[15] 4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting. Retrieved June 8, 2023, from https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-presents-positive-interim-data-aerosolized-4d-710-phase-12[16] Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials. Retrieved June 8, 2023, from https://www.businesswire.com/news/home/20230607005685/en/[17] BioInvent Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors. Retrieved June 8, 2023, from https://www.accesswire.com/759774/BioInvent-Announces-Additional-Efficacy-Data-from-Intravenous-Part-of-Phase-12-Trial-with-BI-1206-in-Solid-Tumors[18] Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma. Retrieved June 8, 2023, from https://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-announces-first-patient-dosed-phase-12[19] BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO. Retrieved June 8, 2023, from https://www.globenewswire.com/news-release/2023/06/02/2681039/0/en/BioNTech-and-OncoC4-Present-Positive-Phase-1-2-Data-for-Antibody-Candidate-BNT316-ONC-392-in-Hard-to-Treat-NSCLC-at-ASCO.html[20] Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session. Retrieved June 8, 2023, from https://www.prnewswire.com/news-releases/vigeo-therapeutics-will-present-new-clinical-and-immune-profiling-data-from-ph-iii-expansion-study-in-gbm-patients-in-asco-poster-oral-session-301840335.html[21] Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Retrieved June 8, 2023, from https://ir.replimune.com/news-releases/news-release-details/replimune-presents-rp1-data-ignyte-anti-pd1-failed-melanoma[22] Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting. Retrieved June 8, 2023, from https://www.globenewswire.com/news-release/2023/06/03/2681518/0/en/Allogene-Therapeutics-Presents-Updated-ALLO-501-501A-Phase-1-Data-in-Large-B-Cell-Lymphoma-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html[23] AFFIMED PRESENTS AFM24 MONOTHERAPY DATA IN NON-SMALL CELL LUNG CANCER AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND PROVIDES STRATEGIC UPDATE ON AFM24 DEVELOPMENT PLAN. Retrieved June 8, 2023, from https://www.affimed.com/affimed-presents-afm24-monotherapy-data-in-non-small-cell-lung-cancer-at-the-annual-meeting-of-the-american-society-of-clinical-oncology-and-provides-strategic-update-on-afm24-development-plan-2/[24] Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma. Retrieved June 8, 2023, from https://www.prnewswire.com/news-releases/janssen-presents-longer-term-talquetamab-follow-up-data-showing-overall-response-rates-of-more-than-70-percent-in-heavily-pretreated-patients-with-multiple-myeloma-301841822.html[25] IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting. Retrieved June 8, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2681908/0/en/IN8bio-Announces-Positive-INB-200-Phase-1-Data-Update-in-Glioblastoma-at-the-2023-ASCO-Annual-Meeting.html[26] NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Retrieved June 9, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2681899/0/en/NKGen-Biotech-Announces-SNK01-Preclinical-and-Phase-I-IIa-Clinical-Data-Presented-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html[27] Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting. Retrieved June 9, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2681923/0/en/Atreca-Presents-Data-from-Ongoing-Phase-1b-Study-of-ATRC-101-in-Patients-with-Select-Advanced-Solid-Tumors-during-Oral-Abstract-Session-at-the-ASCO-2023-Annual-Meeting.html[28] Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) . Retrieved June 9, 2023, from https://www.globenewswire.com/news-release/2023/06/05/2681931/0/en/Morphogenesis-Inc-and-CohBar-Inc-Announce-Positive-Results-from-Phase-1b-Trial-of-IFx-Hu2-0-a-Novel-Personalized-Cancer-Vaccine-in-Checkpoint-Inhibitor-Resistant-Advanced-Merkel-Ce.html[29] Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting . Retrieved June 9, 2023, from https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-the-presentation-of-phase-1-df1001-trinket-dose-escalation-results-at-asco-2023-annual-meeting-301842406.html[30] Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session. Retrieved June 9, 2023, from https://www.prnewswire.com/news-releases/vigeo-therapeutics-will-present-new-clinical-and-immune-profiling-data-from-ph-iii-expansion-study-in-gbm-patients-in-asco-poster-oral-session-301840335.html[31] Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting. Retrieved June 9, 2023, from https://www.globenewswire.com/news-release/2023/06/03/2681519/0/en/Elicio-Therapeutics-Announces-Positive-Interim-Data-from-the-Phase-1-Study-of-an-Investigational-Therapeutic-Cancer-Immunotherapy-ELI-002-in-Patients-with-High-Relapse-Risk-Pancrea.html[32] Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers. . Retrieved June 9, 2023, from https://www.prnewswire.com/news-releases/precigen-announces-positive-phase-1-data-for-off-the-shelf-prgn-2009-adenoverse-immunotherapy-alone-and-in-combination-with-an-investigational-checkpoint-inhibitor-in-patients-with-recurrentmetastatic-hpv-associated-cancers-301841791.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

细胞疗法免疫疗法临床结果基因疗法蛋白降解靶向嵌合体

2023-06-02

·BioSpace

Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

CAMBRIDGE, Mass., June 2, 2023 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new data from its Phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma (rGBM). The data will be presented by Dr. David Peereboom of Cleveland Clinic in a poster discussion session tomorrow, June 3, 2023, from 4:30 – 6:00 PM at the American Society of Clinical Oncology (ASCO) annual meeting being held June 2 – June 6, 2023 in Chicago, IL. VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME). Tsp-1 blocks the CD47 immune checkpoint and engages CD36 to induce tumor cell apoptosis, inhibit angiogenesis, activate cytotoxic T cells (CTL), and reprogram macrophages from the M2 to M1 phenotype. In a phase I/II clinical study in solid tumors (NCT03364400) VT1021 demonstrated promising single-agent clinical activity against recurrent glioblastoma. Among 22 evaluable subjects with rGBM, 3 had a complete response (CR), 1 had a partial response (PR), and 6 had stable disease (SD) with an average study duration of over 120 days. One subject continues to receive VT1021 treatment and has been on study for almost 3 years with no remaining measurable lesion. Historically, rGBM patients have a response rate of less than 5% and a median progression free survival of 48 days. Confirming the role of VT1021 in altering the tumor microenvironment, immune profiling of the GBM patients on the study showed beneficial and sustained changes in CTL parameters and PD-L1+ MDSCs that correlated with response. Specifically, CR/PR subjects showed decreases in PDL1+ MDSCs along with an increase in total CTLs, proliferating CTLs, and CTL/Treg ratio. In contrast, SD and PD subjects exhibited no change or decrease in these three CTL parameters. "The demonstration of the effect of VT1021 on the tumor immune microenvironment and the correlation with clinical outcome are encouraging signs in the development of new therapies for GBM patients" said Dr. David Peereboom of Cleveland Clinic. "To further advance VT1021 as a therapy for GBM, Vigeo is studying the potential of VT1021 in both newly diagnosed and recurrent subjects in an ongoing phase II/III clinical study (NCT03970447)" said Dr. Jing Watnick, COO and co-founder of Vigeo Therapeutics. Presentation Title: Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study. Date & Time: Saturday June 3, 2023 from 4:30PM – 6:00 PM Abstract Session: Central Nervous System Tumors Abstract: 409504 Location: Board # 378 Presenter: David M. Peereboom, MD Professor of Medicine, Cleveland Clinic About VT1021 Vigeo's lead asset, VT1021, is a first-in-class dual-modulating compound that blocks the CD47 immune checkpoint and activates CD36, which induces apoptosis in tumors and endothelial cells, and increases the M1:M2 macrophage ratio. VT1021 achieves these biological effects via stimulation of thrombospondin-1 (Tsp-1). The goal of these dual-modulating effects is conversion of immuno-suppressive, or "cold," tumors that that are associated with poor response to immuno-oncology agents, to immuno-stimulated, or "hot," tumors that are more susceptible to attack from the body's immune system. Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors. About Vigeo Therapeutics Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug development pipeline being led by VT1021, its dual-modulating compound that blocks the CD47 immune checkpoint and reprograms CD36 mediated activities. VT1021 has been investigated as a single agent in a Phase I/II clinical trial in patients with glioblastoma, pancreatic cancer and other solid tumors, and is currently undertaking late-stage clinical studies. For more information visit vigeotx.com

免疫疗法ASCO会议临床结果临床研究

100 项与 VT-1021 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性胶质母细胞瘤	临床3期	德国	朴莱雷斯集团	2019-07-30
复发性胶质母细胞瘤	临床3期	瑞士	Kintara Therapeutics, Inc.	2019-07-30
复发性胶质母细胞瘤	临床3期	德国	Kazia Therapeutics Ltd.	2019-07-30
复发性胶质母细胞瘤	临床3期	加拿大	Vigeo Therapeutics, Inc.	2019-07-30
复发性胶质母细胞瘤	临床3期	澳大利亚	朴莱雷斯集团	2019-07-30
复发性胶质母细胞瘤	临床3期	法国	Vigeo Therapeutics, Inc.	2019-07-30
复发性胶质母细胞瘤	临床3期	瑞士	Kazia Therapeutics Ltd.	2019-07-30
复发性胶质母细胞瘤	临床3期	美国	Vigeo Therapeutics, Inc.	2019-07-30
复发性胶质母细胞瘤	临床3期	澳大利亚	Biohaven Pharmaceuticals, Inc.	2019-07-30
复发性胶质母细胞瘤	临床3期	加拿大	Kintara Therapeutics, Inc.	2019-07-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03364400 (Pubmed) 人工标引	临床1期	晚期恶性实体瘤 TSP-1 \| plasmatic cytokines	-	VT1021	(範顧構鏇觸蓋構餘醖製) = Adverse events (AE) suspected to be related to the study treatment (RTEAEs) are mostly grade 1-2. There are no grade 4 or 5 adverse events. 淵鹹餘鹽觸觸鏇鹹鬱糧 (願鹹壓壓淵糧願鹹壓窪 )	积极	2024-05-21
NCT03364400 (Pubmed) 人工标引	临床1期	晚期恶性实体瘤 TSP-1 \| plasmatic cytokines	-	VT1021 (rGBM)		积极	2024-05-21
NCT03364400 (VT1021-01, Pubmed) 人工标引	临床1期	晚期恶性实体瘤 thrombospondin-1 (TSP-1) \| CD36 \| CD47	38	VT1021 0.5-15.6 mg/kg	(淵範齋鏇簾艱觸製蓋餘) = 願窪範築範選壓襯築繭襯糧鬱範積衊糧積窪鑰 (網鹽網構願蓋齋鹽製窪 ) 更多	积极	2024-01-13
NCT03364400 (ASCO2023)	临床2/3期	胶质母细胞瘤	22	VT1021	(鏇醖憲襯網蓋願廠繭壓) = 鹹醖築齋齋顧顧醖鏇鑰壓鹹鹽網膚鹽襯襯築簾 (壓選糧齋襯製顧繭廠構 ) 更多	积极	2023-05-31
NCT03364400 (Biospace) 人工标引	临床1/2期	胶质母细胞瘤	22	VT1021	(構糧糧鏇窪築鑰鹹鹹醖) = 願簾餘築淵艱範淵鑰醖壓夢淵憲淵襯積製築構 (齋願鏇窪齋鏇鑰獵顧憲 ) 更多	积极	2021-11-16
NCT03364400 (369, SITC2021)	临床1/2期	实体瘤 \| 胰腺癌 CD36 \| CD47 \| Tsp-1	32	VT1021	製醖繭鏇壓顧鏇襯鹽餘(顧範糧壓鏇蓋製網餘製) = 鬱範糧遞夢艱鬱窪窪襯糧範繭襯糧鬱夢蓋糧膚 (築鬱齋構鹹願艱遞遞齋 ) 更多	积极	2021-11-10
NCT03364400 (VT1021, SITC2020)	临床1/2期	晚期恶性实体瘤 CD36 \| CD47	46	VT1021	餘構鏇鑰醖夢鬱廠壓餘(遞製鹹範餘壓窪衊獵夢) = 鏇鬱淵簾蓋選顧鑰衊窪築鬱憲簾夢醖衊簾鹽窪 (積廠窪鬱餘夢淵窪艱繭 )	积极	2020-12-10
NCT03364400 (Biospace) 人工标引	临床1/2期	晚期恶性实体瘤	28	VT1021	(選廠餘築蓋簾憲窪齋鏇) = 網鬱衊鹹築鬱遞範顧積廠顧願鏇鑰顧觸選艱醖 (遞顧夢鬱選鬱網齋積艱 ) 更多	积极	2020-11-09